NEW YORK (360Dx) – Roche on Tuesday said that its PD-L1 assay was approved by the US Food and Drug Administration as a complementary diagnostic for patients with locally advanced or metastatic urothelial carcinoma who are being considered for treatment with AstraZeneca's immunotherapy Imfinzi (durvalumab).